

For Immediate Release

Contact: Sara Lizzo
Berry & Company Public
Relations 212-253-8881 or
slizzo@berrypr.com

CELATOR[®] PHARMACEUTICALS TO PRESENT AT PIPER JAFFRAY HEALTH CARE CONFERENCE and MID-ATLANTIC CAPITAL CONFERENCE

PRINCETON, NJ (November 25, 2008) – Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York and the 2008 Mid-Atlantic Capital Conference in Philadelphia. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentations will be held as follows:

Piper Jaffray Health Care Conference
Tuesday, December 2, 2008 at 3:50pm ET at the New York Palace Hotel

Mid-Atlantic Capital Conference
Wednesday, December 3, 2008 at 2:44pm ET in the Life Science Room of the Pennsylvania Convention Center

About Celator

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex[®], the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com.